BOTHE.BR
Bone Therapeutics SA [BOTHE.BR] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
BOTHE.BR Stock Summary
In the News
BOTHE.BR Financial details
Company Rating
-
Market Cap
0
Income
-
Revenue
-
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
20
Optionable
No
Shortable
Yes
Earnings
30 Oct 2020
P/E
-0.26
Forward P/E
-
PEG
-
P/S
-
P/B
-0.5
P/C
-
P/FCF
-
Quick Ratio
1.6
Current Ratio
2.14
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-
EPS next Y
-
EPS next Q
-
EPS this Y
-18.52%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-9.97%
Revenue last 5Y
89.43%
Revenue Q/Q
-
EPS Q/Q
66.73%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-65%
ROE
751%
ROC
-0.92%
Gross Margin
100%
Oper. Margin
-1199%
Profit Margin
-1293%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.112-1.218
52W High
-
52W Low
-
RSI
-
Rel Volume
6.9
Avg Volume
201.58K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
0.302952
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-
Company Profile
- Volume Average 201.58K
- Employee 20
- CEO Dr. Miguel Forte M.D., Ph.D.
- Headquarters Mont-Saint-Guibert,BE
- IPO Date 2015-02-06
-
Website
https://www.bonetherapeutics.com 
Bone Therapeutics SA, a biotechnology company, engages in the development of cell therapy products for orthopedics and bone diseases. Its products include ALLOB, an allogeneic cell therapy product, which is in Phase I/IIa clinical trial for the treatment of delayed-union fractures and lumbar spinal fusion; and JTA-004, an intra-articular injectable that is in phase III clinical trial to treat osteoarthritic pain in the knee. Bone Therapeutics SA was incorporated in 2006 and is based in Mont-Saint-Guibert, Belgium.
